These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 20811704)

  • 61. Heterogeneity-related anticancer therapy response differences in metastatic colon carcinoma: new hints to tumor-site-based personalized cancer therapy.
    Pan W; Huang S; Zhang J; Zhao B; Wang H; Liu F; Jin K; Mou X
    Hepatogastroenterology; 2013; 60(128):1927-34. PubMed ID: 24719929
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Bispecific antibody to ErbB2 overcomes trastuzumab resistance through comprehensive blockade of ErbB2 heterodimerization.
    Li B; Meng Y; Zheng L; Zhang X; Tong Q; Tan W; Hu S; Li H; Chen Y; Song J; Zhang G; Zhao L; Zhang D; Hou S; Qian W; Guo Y
    Cancer Res; 2013 Nov; 73(21):6471-83. PubMed ID: 24046294
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Novel toll-like receptor 9 agonist induces epidermal growth factor receptor (EGFR) inhibition and synergistic antitumor activity with EGFR inhibitors.
    Damiano V; Caputo R; Bianco R; D'Armiento FP; Leonardi A; De Placido S; Bianco AR; Agrawal S; Ciardiello F; Tortora G
    Clin Cancer Res; 2006 Jan; 12(2):577-83. PubMed ID: 16428503
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models.
    Scheuer W; Friess T; Burtscher H; Bossenmaier B; Endl J; Hasmann M
    Cancer Res; 2009 Dec; 69(24):9330-6. PubMed ID: 19934333
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Trastuzumab (herceptin) targets gastric cancer stem cells characterized by CD90 phenotype.
    Jiang J; Zhang Y; Chuai S; Wang Z; Zheng D; Xu F; Zhang Y; Li C; Liang Y; Chen Z
    Oncogene; 2012 Feb; 31(6):671-82. PubMed ID: 21743497
    [TBL] [Abstract][Full Text] [Related]  

  • 66. MEK5/ERK5 signaling inhibition increases colon cancer cell sensitivity to 5-fluorouracil through a p53-dependent mechanism.
    Pereira DM; Simões AE; Gomes SE; Castro RE; Carvalho T; Rodrigues CM; Borralho PM
    Oncotarget; 2016 Jun; 7(23):34322-40. PubMed ID: 27144434
    [TBL] [Abstract][Full Text] [Related]  

  • 67. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.
    Nagata Y; Lan KH; Zhou X; Tan M; Esteva FJ; Sahin AA; Klos KS; Li P; Monia BP; Nguyen NT; Hortobagyi GN; Hung MC; Yu D
    Cancer Cell; 2004 Aug; 6(2):117-27. PubMed ID: 15324695
    [TBL] [Abstract][Full Text] [Related]  

  • 68. The Akt inhibitor ISC-4 synergizes with cetuximab in 5-FU-resistant colon cancer.
    Allen JE; Gallant JN; Dicker DT; Amin S; Irby RB; Sharma AK; El-Deiry WS
    PLoS One; 2013; 8(3):e59380. PubMed ID: 23555026
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Schedule-dependent synergistic effects of 5-fluorouracil and selumetinib in KRAS or BRAF mutant colon cancer models.
    Jang HY; Kim DH; Lee HJ; Kim WD; Kim SY; Hwang JJ; Lee SJ; Moon DH
    Biochem Pharmacol; 2019 Feb; 160():110-120. PubMed ID: 30579838
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Regulation of ERBB2 receptor by t-DARPP mediates trastuzumab resistance in human esophageal adenocarcinoma.
    Hong J; Katsha A; Lu P; Shyr Y; Belkhiri A; El-Rifai W
    Cancer Res; 2012 Sep; 72(17):4504-14. PubMed ID: 22745369
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Trastuzumab therapy vs tetracycline controlled ERBB2 downregulation: influence on tumour development in an ERBB2-dependent mouse tumour model.
    Hermes M; Schormann W; Brulport M; Uhlemann K; Lupatsch F; Horn LC; Schumann A; Allgaier C; Weishaupt M; Engeland K; Müller GA; Mössner J; Bauer A; Schiffer IB; Gebhard S; Schmidt M; Lausch E; Prawitt D; Wilhelm C; Hengstler JG
    Br J Cancer; 2008 May; 98(9):1525-32. PubMed ID: 18454161
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Multikinase inhibitor regorafenib inhibits the growth and metastasis of colon cancer with abundant stroma.
    Takigawa H; Kitadai Y; Shinagawa K; Yuge R; Higashi Y; Tanaka S; Yasui W; Chayama K
    Cancer Sci; 2016 May; 107(5):601-8. PubMed ID: 26865419
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Anti-Human Epidermal Growth Factor Receptor 2 Monoclonal Antibody H
    Kato Y; Ohishi T; Yamada S; Itai S; Takei J; Sano M; Nakamura T; Harada H; Kawada M; Kaneko MK
    Monoclon Antib Immunodiagn Immunother; 2019 Aug; 38(4):157-161. PubMed ID: 31199696
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Anti-Cancer Effects of Zotarolimus Combined with 5-Fluorouracil Treatment in HCT-116 Colorectal Cancer-Bearing BALB/c Nude Mice.
    Chang GR; Kuo CY; Tsai MY; Lin WL; Lin TC; Liao HJ; Chen CH; Wang YC
    Molecules; 2021 Aug; 26(15):. PubMed ID: 34361836
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Microbead arrays for the analysis of ErbB receptor tyrosine kinase activation and dimerization in breast cancer cells.
    Khan IH; Zhao J; Ghosh P; Ziman M; Sweeney C; Kung HJ; Luciw PA
    Assay Drug Dev Technol; 2010 Feb; 8(1):27-36. PubMed ID: 20035613
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Focal adhesion kinase autophosphorylation inhibition decreases colon cancer cell growth and enhances the efficacy of chemotherapy.
    Heffler M; Golubovskaya VM; Dunn KM; Cance W
    Cancer Biol Ther; 2013 Aug; 14(8):761-72. PubMed ID: 23792569
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Therapeutic anti-cancer activity of antibodies targeting sulfhydryl bond constrained epitopes on unglycosylated RON receptor tyrosine kinase.
    Koh XY; Koh XH; Hwang LA; Ferrer FJ; Rahmat SAB; Lama D; Lane DP
    Oncogene; 2019 Nov; 38(48):7342-7356. PubMed ID: 31417186
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Recombinant Oral Methioninase (o-rMETase) Combined With Oxaliplatinum Plus 5-Fluorouracil Improves Survival of Mice With Massive Colon-Cancer Peritoneal Carcinomatosis.
    Kim MJ; Han Q; Bouvet M; Hoffman RM; Park JH
    Anticancer Res; 2023 Jan; 43(1):19-24. PubMed ID: 36585181
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Oral recombinant methioninase combined with oxaliplatinum and 5-fluorouracil regressed a colon cancer growing on the peritoneal surface in a patient-derived orthotopic xenograft mouse model.
    Park JH; Han Q; Zhao M; Tan Y; Higuchi T; Yoon SN; Sugisawa N; Yamamoto J; Bouvet M; Clary B; Singh SR; Hoffman RM
    Tissue Cell; 2019 Dec; 61():109-114. PubMed ID: 31759402
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Liposomal prednisolone phosphate potentiates the antitumor activity of liposomal 5-fluorouracil in C26 murine colon carcinoma in vivo.
    Patras L; Sylvester B; Luput L; Sesarman A; Licarete E; Porfire A; Muntean D; Drotar DM; Rusu AD; Nagy AL; Catoi C; Tomuta I; Vlase L; Banciu M; Achim M
    Cancer Biol Ther; 2017 Aug; 18(8):616-626. PubMed ID: 28696813
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.